Effectiveness of JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study
Arthritis & Rheumatology · 2025
DOI: 10.1002/art.43014 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Anna Eberhard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Lund University, Malmö, Sweden. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Janus Kinase Inhibitors, Biological Products. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lund University, Swedish Research Council, Swedish Rheumatism Association.
Abstract (Originalsprache)
Objective
To compare the effectiveness of JAK inhibitors (JAKis) and biologic disease‐modifying antirheumatic drugs (bDMARDs) on pain in patients with rheumatoid arthritis.
Methods
In this retrospective study, we investigated patients with a diagnosis of rheumatoid arthritis, starting treatment with a JAKi (n = 1,827), a tumor necrosis factor inhibitor (TNFi; n = 6,422), an interleukin‐6 inhibitor (n = 887), abatacept (n = 1,102), or rituximab (n = 1,149) in 2017 to 2019, using data from several linked Swedish national registers. Differences in change in pain, assessed with a visual analog scale (0–100 mm), from baseline to 3 months, as well as proportions of patients remaining on initial treatment with low pain (visual analog scale pain
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lund University, Malmö, Sweden.
- Karolinska Institutet, Stockholm, Sweden.
- Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
- Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Linköping University, Linköping, Sweden.
ORCID-Profile: Anna Eberhard, Katerina Chatzidionysiou, Alf Kastbom, Tor Olofsson, Carl Turesson
Förderung
- Lund University
- Swedish Research Council
- Swedish Rheumatism Association
Zitieren
APA
Eberhard, A., Di Giuseppe, D., Askling, J., Bergman, S., Bower, H., Chatzidionysiou, K., Forsblad-d'Elia, H., Kastbom, A., Olofsson, T., Frisell, T., & Turesson, C. (2025). Effectiveness of JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.43014
Vancouver
Eberhard A, Di Giuseppe D, Askling J, Bergman S, Bower H, Chatzidionysiou K, et al. Effectiveness of JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study. Arthritis & Rheumatology. 2025. doi:10.1002/art.43014
BibTeX
@article{Eberhard2025,
author = {Eberhard, Anna and Di Giuseppe, Daniela and Askling, Johan and Bergman, Stefan and Bower, Hannah and Chatzidionysiou, Katerina and Forsblad-d'Elia, Helena and Kastbom, Alf and Olofsson, Tor and Frisell, Thomas and Turesson, Carl},
title = {Effectiveness of JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study},
journal = {Arthritis & Rheumatology},
year = {2025},
doi = {10.1002/art.43014}
}
EUVIMED